Cyclosporine
Cyclosporine, also called ciclosporin or cyclosporine A (CsA), is a cyclic peptide immunosuppressant and calcineurin-inhibiting drug.
Cyclosporine, also called ciclosporin or cyclosporine A (CsA), is a cyclic peptide immunosuppressant and calcineurin-inhibiting drug. After binding to cyclophilin, it inhibits calcineurin-dependent activation of T lymphocytes and reduces transcription of interleukin 2 (IL-2) and other immune-signaling mediators. Through this pathway, cyclosporine suppresses components of both cellular and adaptive immune responses and can reduce production of proinflammatory cytokines, including tumor necrosis factor-α (TNF-α).
Cyclosporine is used systemically and topically. Its topical ophthalmic applications are particularly relevant to dry eye disease and keratoconjunctivitis sicca, where treatment is intended to modulate ocular-surface inflammation while limiting systemic exposure. The recent literature also examines cyclosporine in immune-mediated skin and gastrointestinal disease, as well as delivery technologies such as hydrogels, nanostructured lipid carriers, and biodegradable implants. These studies extend the broad theme of cyclosporine therapeutic studies into localized treatment, sustained release, and salvage immunosuppression.
Where the papers sit
10 papers from the last 6 months study cyclosporine directly · updated from PubMed 10 Nov 2026
Study type 2 clinical trials · 3 observational · 1 human data · 4 preclinical
Themes 3 themes
-
Topical Cyclosporine for Dry Eye
Conventional cyclosporine drops are giving way to sustained and tissue-targeted delivery for dry eye disease. Nanostructured lipid carriers, hyaluronic-acid nanomicelles and thermogelling lacrimal platforms aim to prolong ocular residence and improve exposure. Comparative low-concentration drops and immune-response monitoring address clinical effectiveness and mechanism. An inhalable lipid formulation extends the delivery strategy to pulmonary exposure but sits outside the dominant ocular focus.
6 papers · 60%
-
Controlled Cyclosporine Delivery
Cyclosporine delivery is moving toward programmable, sustained release rather than repeated administration. Thermo-switch hydrogels use size-selective diffusion to regulate drug transport, while a TPU/PLDLA implant provides prolonged local release in canine keratitis. Franz-cell testing, T-cell proliferation and interleukin-2 recur as measures of release and immunosuppressive activity. The work is still centered on formulation and delivery optimization rather than comparative clinical outcomes.
2 papers · 20%
-
Others — Cyclosporine Rescue Therapy
Cyclosporine is used as local or systemic rescue treatment for inflammatory complications. Topical therapy is assessed for edematous punctal stenosis with anterior segment OCT, while ciclosporin acutely treats ocrelizumab-induced colitis. Steroid and anti-inflammatory management recur across the cases. Their diseases, anatomical targets and treatment settings remain distinct, with no shared therapeutic direction.
2 papers · 20%
Papers
The 10 papers from the last 6 months that study cyclosporine directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Topical Cyclosporine for Dry Eye (6)
- Comparative study on the clinical effectiveness of low-concentration cyclosporine eye drops in patients with dry eye disease. PloS one · 28 Sept 2026 PMID 42804440
- Nanomicelles self-assembled using cyclosporine A-hyaluronic acid conjugates for dry eye disease treatment. Biomaterials science · 21 Sept 2026 PMID 42764677
- The effect of 0.1% topical ciclosporin a for 12-weeks on the ocular surface innate and adaptive immune response in dry eye disease: protocol for a randomized controlled clinical trial. Annals of medicine · 19 Sept 2026 PMID 42762229
- Thermogelling lacrimal duct-applied therapeutic platform for dry eye syndrome. Journal of controlled release : official journal of the Controlled Release Society · 29 Aug 2026 PMID 42668069
- Inhalable solid lipid nanoparticles of cyclosporine A for prolonged pulmonary exposure: nano-in-micro particles prepared with fine droplet drying process. International journal of pharmaceutics · 9 Aug 2026 PMID 42571807
- Optimization and formulation of cyclosporine-loaded nanostructured lipid carriers (NLCs) for the management of dry eye syndrome by using centre composite design approaches. International ophthalmology · 30 Jul 2026 PMID 42533216
Controlled Cyclosporine Delivery (2)
- Bidirectional thermo-switch hydrogels with size-selective diffusion for programmable delivery of medicines. International journal of pharmaceutics · 28 Jul 2026 PMID 42521062
- A Sustained-Release Thermoplastic Polyurethane/Poly L-Lactide-Co-DL-Lactide (TPU/PLDLA) Cyclosporine-A Implant for the Treatment of Canine Keratoconjunctivitis Sicca: A Retrospective Case Series. Veterinary ophthalmology · 27 May 2026 PMID 42192580
Others — Cyclosporine Rescue Therapy (2)
- Anterior segment OCT-based assessment of efficacy of topical cyclosporine in edematous punctal stenosis. International ophthalmology · 10 Sept 2026 PMID 42720832
- Ocrelizumab-induced colitis acutely managed with ciclosporin. BMJ case reports · 22 Jul 2026 PMID 42486658
By study type
Clinical trials (2)
- Comparative study on the clinical effectiveness of low-concentration cyclosporine eye drops in patients with dry eye disease. PloS one · 28 Sept 2026 PMID 42804440
- The effect of 0.1% topical ciclosporin a for 12-weeks on the ocular surface innate and adaptive immune response in dry eye disease: protocol for a randomized controlled clinical trial. Annals of medicine · 19 Sept 2026 PMID 42762229
Observational studies and case reports (3)
- Anterior segment OCT-based assessment of efficacy of topical cyclosporine in edematous punctal stenosis. International ophthalmology · 10 Sept 2026 PMID 42720832
- Ocrelizumab-induced colitis acutely managed with ciclosporin. BMJ case reports · 22 Jul 2026 PMID 42486658
- A Sustained-Release Thermoplastic Polyurethane/Poly L-Lactide-Co-DL-Lactide (TPU/PLDLA) Cyclosporine-A Implant for the Treatment of Canine Keratoconjunctivitis Sicca: A Retrospective Case Series. Veterinary ophthalmology · 27 May 2026 PMID 42192580
Human data, design not indexed (1)
- Optimization and formulation of cyclosporine-loaded nanostructured lipid carriers (NLCs) for the management of dry eye syndrome by using centre composite design approaches. International ophthalmology · 30 Jul 2026 PMID 42533216
Preclinical: animal, cell and lab studies (4)
- Nanomicelles self-assembled using cyclosporine A-hyaluronic acid conjugates for dry eye disease treatment. Biomaterials science · 21 Sept 2026 PMID 42764677
- Thermogelling lacrimal duct-applied therapeutic platform for dry eye syndrome. Journal of controlled release : official journal of the Controlled Release Society · 29 Aug 2026 PMID 42668069
- Inhalable solid lipid nanoparticles of cyclosporine A for prolonged pulmonary exposure: nano-in-micro particles prepared with fine droplet drying process. International journal of pharmaceutics · 9 Aug 2026 PMID 42571807
- Bidirectional thermo-switch hydrogels with size-selective diffusion for programmable delivery of medicines. International journal of pharmaceutics · 28 Jul 2026 PMID 42521062
Written from 10 PubMed abstracts, each one listed by PMID above. Published: 2026-09-21. Drafted by language models from published abstracts; not medical advice.